CSF Aβ1–42, but not p-Tau181, differentiates aMCI from SCI

Rizzi, Liara; Portal, Marcelle Maria; Batista, Carlos Eduardo Alves; Missiaggia, Luciane; Roriz‐Cruz, Matheus

doi:10.1016/j.brainres.2017.10.008

Cited by 9 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, we verified that 45.16% of aMCI individuals who completed the follow-up progressed to ADD after 5 years, corresponding to an annual conversion rate of approximately 9%, which is in agreement with previous studies [25,26]. Prediction of ADD in a short period of time appears much more relevant in a clinical perspective than prediction of dementia in a 6 17 †ADD Alzheimer's disease dementia, aMCI amnestic mild cognitive impairment, AUC area under the curve, ROC receiver operating characteristic. ‡Youden index was used more distant future.…”

Section: Discussionsupporting

confidence: 91%

“…This cohort underwent lumbar puncture followed by CSF biomarkers evaluation and was enrolled in the study until 2018. The baseline cross-sectional and the 3year follow-up studies have already been previously published [5,6]. In brief, patients were enrolled in a systematic way with clinical evaluations by a behavioral/geriatric neurologist and a neuropsychological specialist in order to detect progression to ADD in the aMCI group.…”

Section: Subjectsmentioning

confidence: 99%

See 1 more Smart Citation

Value of CSF Biomarkers in Predicting Risk of Progression from aMCI to ADD in a 5-Year Follow-Up Cohort

Rizzi

Missiaggia

Schwartz

et al. 2020

SN Compr. Clin. Med.

Self Cite

View full text Add to dashboard Cite

The aim of this study is to approach cerebrospinal fluid (CSF) Aβ 1-42 and p-Tau 181 as risks factors in predicting progression from amnestic mild cognitive impairment (aMCI) to Alzheimer's disease dementia (ADD) in a 5-year follow-up. Forty-two individuals diagnosed as aMCI or subjective cognitive impairment (SCI) were evaluated in 2013 and reevaluated in 2018. CSF Aβ 1-42 and p-Tau 181 were measured by immunoenzymatic assay. Differences in cognitive performance between endpoint and baseline were verified by neuropsychological tests. Of the aMCI individuals, 45.2% progressed to ADD in 5 years. The relative risk to develop ADD in individuals with aMCI and Aβ 1-42 < 618.5 pg/mL was 5.8 times higher than in those whose levels were above this cutoff (P = 0.0011). Moreover, the relative risk among those in which the p-Tau 181 /Aβ 1-42 ratio was higher than 0.135 was 3.83 times greater (P = 0.0001). Both Aβ 1-42 and p-Tau 181 levels explained 47.5% of ΔCERADs variance (P < 0.001), whereas Aβ 1-42 alone explained 38.6% (P < 0.001). Aβ 1-42 provided 5.8 times higher cumulative risk to the progression from aMCI to ADD in a 5-year follow-up. The p-Tau 181 /Aβ 1-42 ratio was no better than Aβ 1-42 alone. However, p-Tau 181 levels helped to explain an extra 9% of ΔCERADs variance.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Subjectsmentioning

confidence: 99%

Value of CSF Biomarkers in Predicting Risk of Progression from aMCI to ADD in a 5-Year Follow-Up Cohort

Rizzi

Missiaggia

Schwartz

et al. 2020

SN Compr. Clin. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…When compared to MCI, the SCD individuals showed significantly lower levels of t-tau and p-tau, whereas differences in the Aβ42 levels were less pronounced [91]. Furthermore, a recent study reported significantly lower levels of Aβ42 in SCD than the controls, despite similar levels of t-tau and p-tau [92]. In a recent paper, 46% of SCD displayed brain amyloidosis, whereas 18% of them showed preclinical AD (A+T+) at CSF profile [93].…”

Section: Pre-mci: Neuropsychological and Biomarkers Findingsmentioning

confidence: 99%

Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals

et al. 2019

View full text Add to dashboard Cite

Alzheimer’s disease (AD) pathology begins decades before the onset of clinical symptoms. It is recognized as a clinicobiological entity, being detectable in vivo independently of the clinical stage by means of pathophysiological biomarkers. Accordingly, neuropathological studies that were carried out on healthy elderly subjects, with or without subjective experience of cognitive decline, reported evidence of AD pathology in a high proportion of cases. At present, mild cognitive impairment (MCI) represents the only clinically diagnosed pre-dementia stage. Several attempts have been carried out to detect AD as early as possible, when subtle cognitive alterations, still not fulfilling MCI criteria, appear. Importantly, pre-MCI individuals showing the positivity of pathophysiological AD biomarkers show a risk of progression similar to MCI patients. In view of successful treatment with disease modifying agents, in a clinical setting, a timely diagnosis is mandatory. In clinical routine, biomarkers assessment should be taken into consideration whenever a subject with subtle cognitive deficits (pre-MCI), who is aware of his/her decline, requests to know the cause of such disturbances. In this review, we report the available neuropsychological and biomarkers data that characterize the pre-MCI patients, thus proposing pre-MCI as the first clinical manifestation of AD.

show abstract

“…The total number of participants recruited in all the studies was 7,035 (mean 234.5±274.23), with a mean age of 52.87 years (SD±7.79) and female predominance (4,355 individuals; 61.9%). Only one study analyzed biomarkers in individuals with SCD 13 , while another study analyzed SCD and individuals who converted from nondemented to dementia 14 .…”

Section: Resultsmentioning

confidence: 99%

Evaluating subjective cognitive decline: a systematic review of tools available for evaluating cognitive complaints in Portuguese

Borelli

Labrea

Leal-Conceição

et al. 2021

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Background: Subjective cognitive decline (SCD) is a perception that is not objectively measured in screening tests. Although many tools are available for evaluating SCD, no single gold standard is available for classifying individuals as presenting SCD, in the Portuguese-speaking population. The aim of this study was to systematically review the literature for tools used to evaluate SCD in the Portuguese-speaking population. Methods: Four databases (Web of Science, SciELO, LILACS and MEDLINE) were primarily utilized in this study (Phase 1). Subsequently, we conducted a manual search of the literature (Phase 2). We then retrieved tools for critical evaluation (Phase 3). Studies that matched the inclusion criteria were analyzed. We summarized the features of each tool in terms of the number of questions, scoring system, benefits and deficiencies, translation and validity. Results: A total of 30 studies utilizing four questionnaires and seven different single questions were found. The tools retrieved were the Memory Assessment Questionnaire (MAC-Q; 12/30 studies), single-question methods (7/30 studies), Subjective Memory Complaint Scale (SMC scale; 5/30 studies), Prospective and Retrospective Memory Questionnaire (PRMQ; 3/30 studies) and Memory Complaint Scale (MCS; 3/30 studies). Only two were formally translated and validated for the Portuguese speaking population (PRMQ and MCS). Conclusions: In summary, SCD is still underinvestigated in Portuguese-speaking countries. The MAC-Q was the most commonly used tool in Portuguese, despite its lack of formal translation and validation for the Portuguese-speaking population. Further studies are required in order to develop and validate a screening tool that includes questions for detecting SCD-plus features and affective symptoms, so as to improve its predictive value.

show abstract

CSF Aβ1–42, but not p-Tau181, differentiates aMCI from SCI

Abstract: CSF Aβ, but not p-Tau level was significantly associated with aMCI.

Cited by 9 publications

References 26 publications

Value of CSF Biomarkers in Predicting Risk of Progression from aMCI to ADD in a 5-Year Follow-Up Cohort

Value of CSF Biomarkers in Predicting Risk of Progression from aMCI to ADD in a 5-Year Follow-Up Cohort

Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals

Evaluating subjective cognitive decline: a systematic review of tools available for evaluating cognitive complaints in Portuguese

Contact Info

Product

Resources

About